Elena Izaga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elena Izaga has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Germán Calle-Pérez
Cardiology Department, Hospital Puerta del Mar, Cádiz, Spain; Instituto de Investigación e Innovación en Ciencias Biomédicas de Cádiz, INiBICA, Spain
2 shared publications- Ignacio Jesús Amat Santos
Cardiology Department University Clinic Hospital of Valladolid Valladolid Spain
2 shared publications Livia Gheorghe
Cardiology Department, Hospital Puerta del Mar, Cádiz, Spain; Instituto de Investigación e Innovación en Ciencias Biomédicas de Cádiz, INiBICA, Spain
2 shared publicationsAbhishek Kumar
1 shared publication- Alba Abril Molina
Hospital Universitario Virgen del Rocío
1 shared publication - Albert Massó van Roessel
Hospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau, CIBERCV, ISCIII
1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19)
Clinical Outcomes and Valve Performance of Intra‐Annular Self‐Expanding Transcatheter Aortic Valve in Valve‐in‐Valve Procedures: Insights From the NAViV Registry
Background: Most evidence for transcatheter aortic valve replacement (TAVR) for valve‐in‐valve procedures comes from balloon‐expandable and supra‐annular self‐expanding valves. However, data on intra‐annular self‐expanding valves remain limited. The objectives of this registry were to evaluate the short‐ and midterm outcomes of ViV‐TAVR using the intra‐annular self‐expanding valve Navitor platform in a real‐world setting. Methods: The NAViV (Navitor Valve‐in‐Valve) registry is a retrospective, multicenter study that included 200 patients who underwent valve‐in‐valve TAVR with the Portico/Navitor systems. The primary end point was 30‐day device success. Secondary outcomes included intraprocedural technical success, early safety, and all‐cause death and major adverse events at 2 years. Results: The cohort had a high‐risk profile and a high prevalence of small surgical bioprostheses (internal diameter ≤21 mm in 86% of the patients). Technical success was achieved in 96%, with an in‐hospital mortality rate of 2% and early safety at 30 days of 84%. Mean residual gradients after TAVR were low (14 [interquartile range, 10–20] mm Hg), and residual significant aortic regurgitation was rare (1%). Device success was 73.5%, with high residual gradients (≥20 mm Hg) being the main reason for device failure. Two‐year survival and major adverse events were 85.6% and 69.8%, respectively; with low residual gradients and baseline significant AR being independently associated with higher survival. Conclusions: Valve‐in‐valve TAVR using the Portico/Navitor intra‐annular self‐expanding valve demonstrates a favorable procedural safety profile, sustained valve performance, and encouraging midterm survival in intermediate‐ and high‐risk populations. Larger and comparative studies are warranted to confirm these findings.
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19)
Open AccessClinical Outcomes and Valve Performance of Intra‐Annular Self‐Expanding Transcatheter Aortic Valve in Valve‐in‐Valve Procedures: Insights From the NAViV Registry
Background: Most evidence for transcatheter aortic valve replacement (TAVR) for valve‐in‐valve procedures comes from balloon‐expandable and supra‐annular self‐expanding valves. However, data on intra‐annular self‐expanding valves remain limited. The objectives of this registry were to evaluate the short‐ and midterm outcomes of ViV‐TAVR using the intra‐annular self‐expanding valve Navitor platform in a real‐world setting. Methods: The NAViV (Navitor Valve‐in‐Valve) registry is a retrospective, multicenter study that included 200 patients who underwent valve‐in‐valve TAVR with the Portico/Navitor systems. The primary end point was 30‐day device success. Secondary outcomes included intraprocedural technical success, early safety, and all‐cause death and major adverse events at 2 years. Results: The cohort had a high‐risk profile and a high prevalence of small surgical bioprostheses (internal diameter ≤21 mm in 86% of the patients). Technical success was achieved in 96%, with an in‐hospital mortality rate of 2% and early safety at 30 days of 84%. Mean residual gradients after TAVR were low (14 [interquartile range, 10–20] mm Hg), and residual significant aortic regurgitation was rare (1%). Device success was 73.5%, with high residual gradients (≥20 mm Hg) being the main reason for device failure. Two‐year survival and major adverse events were 85.6% and 69.8%, respectively; with low residual gradients and baseline significant AR being independently associated with higher survival. Conclusions: Valve‐in‐valve TAVR using the Portico/Navitor intra‐annular self‐expanding valve demonstrates a favorable procedural safety profile, sustained valve performance, and encouraging midterm survival in intermediate‐ and high‐risk populations. Larger and comparative studies are warranted to confirm these findings.
- Top Cited Papers
- 21 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (14) , 1895-1905
Drug-Coated Balloon–Based Angioplasty for Chronic Total Occlusions
- 21 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (14) , 1895-1905
Top Cited PapersDrug-Coated Balloon–Based Angioplasty for Chronic Total Occlusions
- 1 February 2021
- Published by Elsevier in The American Journal of Cardiology
- Vol. 141, 31-37
Continuous Thermodilution Method to Assess Coronary Flow Reserve
- 1 February 2021
- Published by Elsevier in The American Journal of Cardiology
- Vol. 141, 31-37
Continuous Thermodilution Method to Assess Coronary Flow Reserve
- 1 December 2020
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 36 (12) , 1978.e5-1978.e8
Multiple Intracardiac and Paradoxical Thrombi Caused by a Thrombus Entrapped in a Patent Foramen Ovale
- 1 December 2020
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 36 (12) , 1978.e5-1978.e8
Multiple Intracardiac and Paradoxical Thrombi Caused by a Thrombus Entrapped in a Patent Foramen Ovale